MCID: ONC002
MIFTS: 50

Onchocerciasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 11 19 58 75 53 2 43 14 16 71 31 33
Infection by Onchocerca Volvulus 11 33
River Blindness 19 2
Onchocerca Volvulus Infection 11
Onchocerciasis, Ocular 71
Onchocerca Infestation 33
Blinding Filariasis 33
Robles' Disease 19
Robles Disease 33
Onchocercosis 33
Volvulosis 11
Craw-Craw 33
Robles 33

Characteristics:


Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:11678
ICD9CM 34 125.3
MeSH 43 D009855
NCIt 49 C34861
SNOMED-CT 68 38539003
ICD10 31 B73
MESH via Orphanet 44 D009855 D015827
ICD10 via Orphanet 32 B73
UMLS via Orphanet 72 C0029001 C0029002
Orphanet 58 ORPHA2737
UMLS 71 C0029001 C0029002

Summaries for Onchocerciasis

GARD: 19 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin Onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis-like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes, and sensitivity to light (photophobia). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by Onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa.

MalaCards based summary: Onchocerciasis, also known as infection by onchocerca volvulus, is related to loiasis and sclerosing keratitis. An important gene associated with Onchocerciasis is IL5 (Interleukin 5), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Innate Immune System. The drugs Anticonvulsants and Vitamins have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are immune system and hematopoietic system

CDC: 2 Onchocerciasis, or River Blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called River Blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers and the infection can result in blindness. In addition to visual impairment or blindness, onchocerciasis causes skin disease, including nodules under the skin or debilitating itching. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

Orphanet: 58 A form of filariasis, caused by the parasitic worm Onchocerca volvulus, transmitted by the black fly. The infection can either be asymptomatic or manifest as an ocular disease (river blindness) with itchy eyes, erythema, photophobia, onchodermatitis or onchocercal skin disease (classified into acute papular, chronic papular, lichenified, atrophic, and depigmentated) and onchocercomas (over bony prominences). Other classic clinical manifestations are ichthyosis-like lesions (''lizard skin'') and ''hanging groin'', which may be associated with lymphadenopathy.

Disease Ontology: 11 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

Wikipedia: 75 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 loiasis 31.3 STH IL5 IL4 IL13 EPX CCL11
2 sclerosing keratitis 31.2 RBP3 IL2
3 filariasis 30.9 STH SERPINA3 IL5 IL4 IL2 IL13
4 filarial elephantiasis 30.9 STH IL5 IL4 IL2 IL13
5 anterior uveitis 30.9 SERPINA3 RBP3 IL2
6 exanthem 30.8 IL4 IL2 CSF2
7 uveitis 30.7 RBP3 IL4 IL2 CCL11
8 tetanus 30.5 IL5 IL4 IL2 IL13
9 ascaris lumbricoides infection 30.5 STH IL5 IL4 IL13
10 schistosomiasis 30.4 RNASE3 IL5 IL4 IL2 IL13 IGHE
11 posterior uveitis 30.2 RBP3 IL5 IL2 IL13
12 cysticercosis 30.1 STH IL5 IL4 IGHE
13 elephantiasis 30.1 STH RNASE3 IL5 IL4 IL13 ELANE
14 cellulitis 30.1 RNASE3 IL5 CSF2
15 scabies 30.0 STH IL5 IL4 IL13
16 ige responsiveness, atopic 30.0 RNASE3 IL5 IL4 IL13 IGHE
17 leishmaniasis 29.9 IL5 IL4 IL2 IL13
18 leprosy 3 29.8 SERPINA3 IL5 IL4 IL2 IL13 HLA-DQA1
19 stomatitis 29.7 IL4 IL2 CSF2
20 eye disease 29.7 SERPINA3 RBP3 IL5 IL4 IL2 IL13
21 hypereosinophilic syndrome 29.7 RNASE3 IL5 IL4 IL2 IL13 IGHE
22 conjunctivitis 29.7 RNASE3 IL5 IL4 IL2 IL13 IGHE
23 fungal infectious disease 29.6 IL5 IL4 IL2 IL13 CSF2
24 trichuriasis 29.5 STH SERPINA3 IL13
25 dermatitis 29.5 RNASE3 IL5 IL4 IL2 IL13 IGHE
26 urinary schistosomiasis 29.5 STH RNASE3 IL5 IL4 IL13 IGHE
27 keratoconjunctivitis 29.5 RNASE3 IL5 IL4 IL2 IL13 CCL11
28 rubella 29.5 IL5 IL4 IL2 HLA-DQA1 CALR
29 severe combined immunodeficiency 29.5 IL5 IL4 IL2 IL13 IGHE CSF2
30 strongyloidiasis 29.4 STH IL5 IL4 IL13 IGHE CCL11
31 podoconiosis 29.4 STH HLA-DQA1
32 allergic conjunctivitis 29.4 RNASE3 IL5 IL4 IL2 IL13 IGHE
33 sarcoidosis 1 29.3 SERPINA3 IL2 IL13 CCL5 CCL11
34 intestinal schistosomiasis 29.3 STH IL5 IL4 IL2 IL13
35 toxocariasis 29.2 STH RNASE3 IL5 IL4 IL13 IGHE
36 hyper ige syndrome 29.1 RNASE3 IL4 IGHE CSF2 CCL7 CCL11
37 skin disease 29.0 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
38 parasitic helminthiasis infectious disease 29.0 STH SERPINA3 RNASE3 IL5 IL4 IL2
39 pulmonary eosinophilia 28.6 RNASE3 IL5 IL4 IL13 EPX CSF2
40 autoimmune disease 28.5 RBP3 IL5 IL4 IL2 IL13 HLA-DQA1
41 immune deficiency disease 28.5 SERPINA3 IL4 IL2 IL13 CSF2 CCL7
42 allergic disease 28.1 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
43 malaria 27.5 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
44 dermatitis, atopic 27.5 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
45 volvulus of midgut 11.2
46 epilepsy 10.7
47 keratitis, hereditary 10.6
48 nodding syndrome 10.5
49 punctate epithelial keratoconjunctivitis 10.4
50 3-methylglutaconic aciduria, type iii 10.4

Graphical network of the top 20 diseases related to Onchocerciasis:



Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

MGI Mouse Phenotypes related to Onchocerciasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.8 CCL11 CCL5 CCL7 CSF2 ELANE EPX
2 hematopoietic system MP:0005397 9.5 CCL11 CCL5 CCL7 CSF2 DSG1 ELANE

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anticonvulsants Phase 4
2 Vitamins Phase 3
3
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
4
Azithromycin Approved Phase 2 83905-01-5 447043
5
Rifampicin Approved Phase 2 13292-46-1 135512673 5381226 135900090
6
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 9812710 6427057
7
Albendazole Approved, Vet_approved Phase 2 54965-21-8 2082
8
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
9
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
10 Anti-Bacterial Agents Phase 2
11 Antitubercular Agents Phase 2
12 Antibiotics, Antitubercular Phase 2
13 Antimitotic Agents Phase 2
14 Antiprotozoal Agents Phase 2
15 Tubulin Modulators Phase 2
16
Sodium citrate Approved, Investigational 68-04-2 23431961
17
Mebendazole Approved, Vet_approved 31431-39-7 4030
18
Piperazine Approved, Vet_approved 110-85-0 4837
19
Diethylcarbamazine Approved, Investigational, Vet_approved 90-89-1 3052
20
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
21 Calcium, Dietary
22 Anticoagulants
23 Citrate
24 Piperazine citrate
25 DMP 777 157341-41-8
26 Chelating Agents
27
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a Completed NCT03852303 Phase 4 ivermectin
2 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
3 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana. Completed NCT02078024 Phase 3 IVM plus ALB;IVM
4 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
5 A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
6 A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis Recruiting NCT03876262 Phase 3 Moxidectin;Ivermectin
7 A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas Recruiting NCT04311671 Phase 3 Moxidectin;Ivermectin
8 Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients Completed NCT04049630 Phase 2 LEV 1 mg/kg;LEV 1,5 mg/kg;LEV 2,5 mg/kg;Placebo
9 A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
10 Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala Completed NCT00127504 Phase 2 Rifampin;Azithromycin
11 Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients Recruiting NCT04049851 Phase 2 Moxidectin 2 MG Oral Tablet;Ivermectin 3Mg Tab;Placebo oral tablet
12 A Phase-II, Randomised, Double-blind, Parallel-group Trial to Investigate Emodepside (BAY 44-4400) in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Pharmacodynamics, Pharmacokinetics and Dose-Response Relationship for Efficacy (Proof-of-Concept); Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics Recruiting NCT05180461 Phase 2 emodepside;matching placebo of emodepside;ivermectin;matching placebo of ivermectin
13 A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics Recruiting NCT04913610 Phase 2 ABBV-4083;Placebo for ABBV-4083;Albendazole;Placebo for Albendazole;Placebo for Ivermectin;Ivermectin
14 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Active, not recruiting NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
15 A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection Withdrawn NCT01035619 Phase 2 moxidectin
16 An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Active, not recruiting NCT03962062 Phase 1 Moxidectin
17 Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug Not yet recruiting NCT05084560 Phase 1 AWZ1066S;Placebo
18 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Unknown status NCT03653975
19 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
20 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
21 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
22 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
23 Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis Completed NCT03517462 Ivermectin 3Mg Tab
24 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
25 Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa Not yet recruiting NCT04035174

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ivermectin

Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

Organs/tissues related to Onchocerciasis:

MalaCards : Skin, Eye, T Cells, Salivary Gland, Neutrophil, Breast, Lymph Node

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 4252)
# Title Authors PMID Year
1
Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy. 53 62
17302900 2007
2
Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naïve patients from Cameroon, and its relationship with fertility of the worms. 53 62
16197589 2006
3
Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). 53 62
12443893 2002
4
Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. 53 62
11169280 2000
5
Pathophysiological roles of calreticulin in autoimmune disease. 53 62
10320638 1999
6
Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfected with intestinal nematodes and in urinary schistosomiasis. 53 62
10206116 1999
7
Characterization of human immune responses to the cytosolic superoxide dismutase and glutathione S-transferase from Onchocerca volvulus. 53 62
9294549 1997
8
The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. 53 62
9176114 1997
9
Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. 53 62
9025985 1996
10
Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. 53 62
8627086 1996
11
A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. 53 62
7836063 1994
12
Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis. 53 62
7520419 1994
13
Regulation of IL-5 in onchocerciasis. A critical role for IL-2. 53 62
8099937 1993
14
Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. 53 62
7680295 1993
15
Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus. 53 62
1602002 1992
16
Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. 53 62
1918387 1991
17
Analysis of aqueous humour in ocular onchocerciasis. 53 62
2036808 1991
18
Cell-mediated immunity against human retinal extract, S-antigen, and interphotoreceptor retinoid binding protein in onchocercal chorioretinopathy. 53 62
2210999 1990
19
Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. 53 62
2365568 1990
20
Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. 53 62
2378211 1990
21
Feline ocular onchocercosis by Onchocerca lupi: Phylogenetic insights and implication for veterinary health. 62
36283498 2023
22
Morphological description and multilocus genotyping of Onchocerca spp. in red deer (Cervus elaphus) in Switzerland. 62
36420351 2022
23
Tropical parasitic itch in returned travellers and immigrants from endemic areas. 62
35793476 2022
24
Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study. 62
36240827 2022
25
Prevalence of epilepsy in Ndom Health District (Littoral Region, Cameroon) after long-term ivermectin-based preventive chemotherapy for the control of onchocerciasis. 62
36252289 2022
26
Integrated xenosurveillance of Loa loa, Wuchereria bancrofti, Mansonella perstans and Plasmodium falciparum using mosquito carcasses and faeces: A pilot study in Cameroon. 62
36322515 2022
27
Two Nigerian States (Plateau and Nasarawa) Have Eliminated Transmission of Human Onchocerciasis-A Report of Post-ivermectin Mass Drug Administration Surveillance. 62
36450227 2022
28
Identification of the onchocerciasis vector in the Kakoi-Koda focus of the Democratic Republic of Congo. 62
36331979 2022
29
Onchocerciasis in the Ntui Health District of Cameroon: epidemiological, entomological and parasitological findings in relation to elimination prospects. 62
36443885 2022
30
Status of Onchocerca volvulus (Spirurida: Onchocercidae) Transmission and Effect of Climatic Variables on the Vector Population Dynamics After Two Decades of Ivermectin-based Preventive Chemotherapy in the Mbam Valley (Centre Region, Cameroon). 62
36111691 2022
31
Direct proteomic detection and prioritization of 19 onchocerciasis biomarker candidates in humans. 62
36435333 2022
32
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. 62
36327052 2022
33
Implication of apoptosis and oxidative stress in mitigation of ivermectin long-term hazards by zinc nanoparticles in male rabbits. 62
36372859 2022
34
CT of Sacral Fractures: Classification Systems and Management. 62
36112523 2022
35
Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin. 62
36357828 2022
36
A cross-sectional study of Simulium damnosum sensu lato breeding sites and species distribution in Sudan savanna, mixed savanna-forest and rainforest regions in Cameroon. 62
36271434 2022
37
A call for loiasis to be added to the WHO list of neglected tropical diseases. 62
35500592 2022
38
Genomic analysis, immunomodulation and deep phenotyping of patients with nodding syndrome. 62
36181424 2022
39
High Prevalence of Glaucoma among Patients in an Onchocerciasis Endemic Area (Mahenge, Tanzania). 62
36145478 2022
40
The interruption of transmission of onchocerciasis in Kaduna, Kebbi and Zamfara states, Nigeria: another milestone achievement. 62
36130252 2022
41
WHO Vision 2020: Have We Done It? 62
36178293 2022
42
The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis. 62
36068517 2022
43
Prospects for developing efficient targets for the xenomonitoring and control of Simulium damnosum s.l., the major vectors of onchocerciasis in Africa. 62
35866620 2022
44
Leukoderma with perifollicular sparing: a diagnostic clue of cutaneous onchocerciasis. 62
36038249 2022
45
'There Were Moments We Wished She Could Just Die': The Highly Gendered Burden of Nodding Syndrome in Northern Uganda. 62
35549600 2022
46
Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization. 62
35834918 2022
47
Changes in Onchocerciasis Ov16 IgG4 Rapid Diagnostic Test Results Over One-Month Follow-up: Lessons for Reading Timeframe and Decision-Making. 62
35914689 2022
48
Ivermectin mass drug administration for onchocerciasis elimination: can it reduce the prevalence of scabies in Ethiopia? 62
36156500 2022
49
Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections. 62
35972896 2022
50
Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions. 62
35921329 2022

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 IL5 IL4 IL2 IL13 FCER2 CSF2
2
Show member pathways
13.41 SERPINA3 S100A12 RNASE3 IL5 IL4 IL2
3
Show member pathways
13.36 IL5 IL4 IL2 IL13 CSF2 CCL7
4
Show member pathways
13.24 IL5 IL4 IL2 IL13 CSF2 CCL7
5
Show member pathways
13.15 S100A12 IL5 IL4 IL2 IL13 HLA-DQA1
6
Show member pathways
12.21 IL4 IGHE FCER2 CCL11
7
Show member pathways
12.11 IL5 IL4 IL2 CSF2
8 11.96 CSF2 IL2 IL4 IL5
9 11.92 IL4 IL13 FCER2 CCL11
10 11.84 IL5 IL4 IL2 IL13 HLA-DQA1
11 11.77 IL5 IL4 IL2 IL13
12 11.72 IL5 IL4 IL2 IL13 CSF2
13 11.69 IL5 IL4 IL2 CSF2
14
Show member pathways
11.66 IL5 IL4 IL2 CSF2
15 11.6 IL5 IL4 FCER2 CCL11
16
Show member pathways
11.57 IL13 IL2 IL4 IL5
17 11.48 FCER2 CSF2 CCL5
18 11.38 CCL11 IL13 IL2 IL4 IL5
19 11.3 IL5 IL4 IL2
20 11.28 IL5 IL4 IL13
21 11.17 IL5 IL4 IL2 IL13
22 11.12 IL5 IL4 IL2 IL13 CSF2
23 10.99 IL5 IL4 IL2 IL13 CSF2
24 10.91 IL4 IL2 CSF2
25 10.91 IL5 IL4 IL2 IL13 CSF2 CCL7
26 10.9 IL5 IL4 IL13 CSF2 CCL5 CCL11
27 10.77 IL5 IL4 IL13

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.17 CALR CCL11 CCL5 CCL7 CSF2 ELANE
2 extracellular space GO:0005615 9.83 CALR CCL11 CCL5 CCL7 CSF2 ELANE

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 10.24 IL4 CSF2 CCL7 CCL5 CCL11
2 inflammatory response GO:0006954 10.21 SERPINA3 S100A12 IL5 IL13 CCL7 CCL5
3 chemotaxis GO:0006935 10.17 RNASE3 CCL7 CCL5 CCL11
4 defense response to bacterium GO:0042742 10.16 S100A12 RNASE3 IGHE EPX ELANE
5 negative regulation of inflammatory response GO:0050728 10.15 IL4 IL2 IL13 ELANE
6 neutrophil chemotaxis GO:0030593 10.06 S100A12 CCL7 CCL5 CCL11
7 positive regulation of smooth muscle cell proliferation GO:0048661 10.05 IL13 ELANE CCL5
8 lymphocyte chemotaxis GO:0048247 10 CCL11 CCL5 CCL7
9 positive regulation of immunoglobulin production GO:0002639 9.95 IL5 IL2 IL13
10 monocyte chemotaxis GO:0002548 9.92 CCL11 CCL5 CCL7 S100A12
11 macrophage activation GO:0042116 9.91 CSF2 IL13 IL4
12 eosinophil chemotaxis GO:0048245 9.88 CCL7 CCL5 CCL11
13 positive regulation of natural killer cell chemotaxis GO:2000503 9.86 CCL7 CCL5
14 positive regulation of B cell proliferation GO:0030890 9.86 IL13 IL2 IL4 IL5
15 cellular calcium ion homeostasis GO:0006874 9.85 ELANE CCL7 CCL5 CCL11 CALR
16 negative regulation of complement-dependent cytotoxicity GO:1903660 9.8 IL4 IL13
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 CCL5 CSF2 IL13 IL2 IL4
18 immune response GO:0006955 9.55 IL5 IL4 IL2 IL13 IGHE HLA-DQA1

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.92 IL5 IL4 IL2 CSF2
2 chemokine activity GO:0008009 9.73 CCL7 CCL5 CCL11
3 CCR1 chemokine receptor binding GO:0031726 9.46 CCL7 CCL5
4 cytokine activity GO:0005125 9.44 IL5 IL4 IL2 IL13 CSF2 CCL7
5 CCR chemokine receptor binding GO:0048020 9.43 CCL7 CCL5 CCL11

Sources for Onchocerciasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....